First Commonwealth Financial Corp PA cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,892 shares of the medical research company’s stock after selling 610 shares during the quarter. Thermo Fisher Scientific makes up 1.4% of First Commonwealth Financial Corp PA’s portfolio, making the stock its 18th largest position. First Commonwealth Financial Corp PA’s holdings in Thermo Fisher Scientific were worth $1,309,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of TMO. Ark Investment Management LLC lifted its position in Thermo Fisher Scientific by 2.8% during the 2nd quarter. Ark Investment Management LLC now owns 18,005 shares of the medical research company’s stock worth $3,141,000 after buying an additional 488 shares in the last quarter. Rosenblum Silverman Sutton S F Inc. CA lifted its position in Thermo Fisher Scientific by 1.2% during the 3rd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 44,471 shares of the medical research company’s stock worth $8,414,000 after buying an additional 513 shares in the last quarter. Victory Capital Management Inc. lifted its position in Thermo Fisher Scientific by 3.2% during the 3rd quarter. Victory Capital Management Inc. now owns 18,675 shares of the medical research company’s stock worth $3,533,000 after buying an additional 575 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in Thermo Fisher Scientific by 1.6% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 189,529 shares of the medical research company’s stock worth $35,859,000 after buying an additional 2,940 shares in the last quarter. Finally, Longview Partners Guernsey LTD raised its holdings in shares of Thermo Fisher Scientific by 7.4% in the 3rd quarter. Longview Partners Guernsey LTD now owns 4,564,913 shares of the medical research company’s stock valued at $863,682,000 after purchasing an additional 313,782 shares during the period. 87.63% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on the stock. Leerink Swann reaffirmed an “outperform” rating and issued a $200.00 target price (down from $216.00) on shares of Thermo Fisher Scientific in a report on Monday, December 4th. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 target price on the stock. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Finally, Barclays upped their target price on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $220.50.
TMO stock opened at $214.72 on Wednesday. The firm has a market cap of $84,551.45, a PE ratio of 38.34, a price-to-earnings-growth ratio of 1.54 and a beta of 1.15. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $151.74 and a fifty-two week high of $226.44.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. The firm had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business’s revenue was up 22.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.41 EPS. equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be issued a $0.17 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Wednesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 12.14%.
In other Thermo Fisher Scientific news, Director William G. Parrett sold 1,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $209.80, for a total value of $209,800.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,827 shares of company stock worth $10,606,272. Insiders own 0.49% of the company’s stock.
WARNING: “First Commonwealth Financial Corp PA Has $1.31 Million Holdings in Thermo Fisher Scientific Inc. (TMO)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://ledgergazette.com/2018/03/21/first-commonwealth-financial-corp-pa-has-1-31-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.